KLF9

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, KLF9 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated KLF9 data layer compared with 20 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher KLF9 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KLF9 expression acts as an unfavorable survival marker.

BRCA and UCEC are the cancer types where KLF9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
BRCAOSMedianAll0.1240.579<.00116view →
UCECOSMedianIV0.2310.592.0366view →
Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

KLF9–BRCA (OS)

Kaplan–Meier survival curve for KLF9 mutant vs wild-type samples in BRCA.

Open the BRCA breakdown →

Exploration